Literature DB >> 16039579

Oscillating CD8(+) T cell effector functions after antigen recognition in the liver.

Masanori Isogawa1, Yoshihiro Furuichi, Francis V Chisari.   

Abstract

When hepatitis B virus (HBV)-specific CD8(+) cytotoxic T lymphocytes (CTLs) are adoptively transferred into HBV transgenic mice, they enter the liver, recognize antigen, secrete interferon gamma (IFNgamma), inhibit viral replication, and kill their target cells, causing hepatitis. In the current study, we examined the impact of antigen recognition on the evolution of the activation phenotype, antiviral effector functions, expansion and contraction kinetics, and compartmentalization of the transferred CTLs. The results reveal that noncytolytic and cytolytic effector functions and expansion-contraction kinetics of the CTLs are regulated asynchronously and in an oscillatory manner as a consequence of antigen recognition in the liver and in association with PD-1 upregulation. We suggest that such oscillations maximize viral clearance and minimize tissue injury during HBV infection and that poor coordination of these events could lead to viral persistence and chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16039579     DOI: 10.1016/j.immuni.2005.05.005

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  79 in total

Review 1.  Evaluation of current cancer immunotherapy: hemato-oncology.

Authors:  Christopher S Hourigan; Hyam I Levitsky
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

2.  Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model.

Authors:  I-Tsu Chyuan; Hwei-Fang Tsai; Horng-Tay Tzeng; Chi-Chang Sung; Chien-Sheng Wu; Pei-Jer Chen; Ping-Ning Hsu
Journal:  Cell Mol Immunol       Date:  2015-02-09       Impact factor: 11.530

Review 3.  Pathogenesis of hepatitis B virus infection.

Authors:  Thomas F Baumert; Robert Thimme; Fritz von Weizsäcker
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 4.  Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells.

Authors:  Barbara Rehermann
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

5.  CD8+ memory T cells appear exhausted within hours of acute virus infection.

Authors:  Martin P Hosking; Claudia T Flynn; Jason Botten; J Lindsay Whitton
Journal:  J Immunol       Date:  2013-09-11       Impact factor: 5.422

6.  Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection.

Authors:  Li-Rung Huang; Dirk Wohlleber; Florian Reisinger; Craig N Jenne; Ru-Lin Cheng; Zeinab Abdullah; Frank A Schildberg; Margarete Odenthal; Hans-Peter Dienes; Nico van Rooijen; Edgar Schmitt; Natalio Garbi; Michael Croft; Christian Kurts; Paul Kubes; Ulrike Protzer; Mathias Heikenwalder; Percy A Knolle
Journal:  Nat Immunol       Date:  2013-04-14       Impact factor: 25.606

7.  Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.

Authors:  Gerald Willimsky; Karin Schmidt; Christoph Loddenkemper; Johanna Gellermann; Thomas Blankenstein
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

8.  Immune effectors required for hepatitis B virus clearance.

Authors:  Priscilla L Yang; Alana Althage; Josan Chung; Holly Maier; Stefan Wieland; Masanori Isogawa; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

Review 9.  Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.

Authors:  John Attanasio; E John Wherry
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 10.  Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection.

Authors:  Christoph Neumann-Haefelin; Hans-Christian Spangenberg; Hubert-E Blum; Robert Thimme
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.